Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
The phase III HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor Tukysa in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer has met its primary endpoint.
Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial.
AccessHope has unveiled new research that demonstrates how remote expert oncology opinions can meaningfully bridge socioeconomic and geographic barriers to facilitate optimal cancer care.
Mayo Clinic administered an investigational radioactive medicine to a patient with hepatocellular carcinoma.
Cancer is a challenging enough diagnosis, but many patients are dealt a second blow, even as they heal: chemo brain.
Researchers at the UC San Diego School of Medicine engineered a new anti-αvβ3 antibody that activates macrophages—a type of immune cell already abundant in advanced αvβ3+ tumors—and were able to trigger anti-tumor responses in both patient tumor samples and in mouse models.
Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with HIF-2α inhibitors developed by UT Southwestern Medical Center.
Taking brain cancer biopsies over time revealed positive changes to the tumor microenvironment, even when traditional imaging scans showed the tumor getting worse, according to a multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute.
A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.
